Searched for
BUDGET PHARMACEUTICAL IMPACT
Over 60% of pharma MSMEs yet to comply with updated manufacturing normsPharma industry officials say the revised Schedule M regulations could require Rs 10-15 crore per facility in upgrades, while talent shorta...- Rupee depreciation: What are the implications for commodities and Indian economy?The Indian rupee experienced a sharp decline in 2026, nearing Rs. 97 against the US dollar before a slight recovery. This depreciation, dri...
- West Asia crisis may soon make everyday goods costlier in IndiaIndia faces a looming price hike on everyday goods as global commodity costs surge due to the West Asia conflict. Manufacturers are absorbi...
- Nifty’s 2 pillars now facing structural headwinds: Ravi Dharamshi's warning on IT & consumptionHis warning carries weight. ValueQuest has been quietly repositioning for months by moving capital away from consumption-oriented exposures...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- “No Bull, no bear—it’s a kangaroo market," says Nilesh Shah amid global uncertaintyIndian markets show a recovery but face a "kangaroo market" due to global risks like West Asian tensions and oil price volatility. Investor...
- Why Motilal Oswal’s BFSI fund is betting big on capital market ecosystem: Prateek Agarwal of Motilal Oswal AMCPrateek Agarwal of Motilal Oswal AMC highlights a shift in financial sector growth from traditional banking to capital markets like AMCs, b...
- Pharma exports fall to five-year low in March amid West Asia crisisIndia's pharma exports saw a sharp 23.17% fall in March. The West Asia war disrupted shipping routes and air transit hubs. This led to incr...
- Trump's 100% tariff on patented drugs has limited impact on Indian pharma, rising protectionism a concern: Syngene MDThe recent decision by US President Donald Trump to impose a 100 per cent tariff on patented pharmaceutical imports to US is unlikely to ca...
- Biopharma Shakti programme key enabler for India's journey towards value leadership: Dr Reddy''s LabWith its 2026 Union Budget, India places a spotlight on the future of healthcare, specifically targeting biologics and biosimilars. A visio...
- Budget for 'pharmacy of the world': What Sitharaman & Co can do to make medicines more affordable in IndiaUnion Budget 2026: India's pharmaceutical landscape is on the brink of a transformative boom. To maintain this upward trajectory, the focus...
- A Budget booster shot for the ‘pharmacy to the world’The announcements made are preventive and curative, benefiting the people of the community. An open platform for the National Digital Healt...
- Pharma industry seeks enhanced funds for healthcare sector, ease of doing biz in BudgetThe industry is also seeking simplification of various processes in order to enhance ease of doing business for the private sector companie...
- 130 companies to announce Q3 results this weekend, just before the budget91 companies will declare their third quarter results on Friday, January 29, the last trading day before the Budget is presented on Monday,...
- Drugs likely to cost more after hike in excise dutyDrugs are expected to cost more due to hike in excise duty to 6% from 5% on formulations and to 12% from 10% on bulk drugs announced by FM ...
- Union Budget 2012-13 to encourage pharma companies to invest more in R&DTax exemption in Budget 2012-13 for in house R&D by another 5 years to 2017 is expected to encourage pharmaceutical companies to invest mor...
- Budget 2012: No major incentive or reform for life science industryContrary to the expectations of the industry, there is no major incentive or reform for life science industry in the Union Budget 2012-13.
- Union Budget 2010: Pharma industry welcomes tax incentives for R&DFinance minister proposed a weighted tax deduction on expenditure incurred in in-house research and development activities to 200 per cent ...
- Pharma exports down on health cost cut in rich nationsIndia's pharmaceutical exports suffered a severe setback in March declining by 21 per cent from a year-ago level as people in the recession...
- Pharma cos may trim clinical research spend as budget shrinksThe clinical research business in India, which has growing at a robust pace over the past few years, is likely to face a slowdown in 2009-1...
Load More
